{"url_path":"/sec/bfri/10-k/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-K/A","doc_date":"2026-07-22","source_url":"https://www.sec.gov/Archives/edgar/data/1858685/0001493152-26-034251-index.html","accession_number":"0001493152-26-034251","cik":"0001858685","ticker":"BFRI","issuer_name":"Biofrontera Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1858685/0001493152-26-034251-index.html","primary_entity_key":"0001858685","primary_entity_name":"Biofrontera Inc."},"word_count":987,"has_tables":true,"body_markdown":"false\nFY\n0001858685\n\n0001858685\n\n2025-01-01\n2025-12-31\n\n0001858685\n\nBFRI:CommonStockParValue0.001PerShareMember\n\n2025-01-01\n2025-12-31\n\n0001858685\n\nBFRI:WarrantsForCommonStockMember\n\n2025-01-01\n2025-12-31\n\n0001858685\n\n2025-06-30\n\n0001858685\n\n2026-03-16\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n \n\n**UNITED\nSTATES**\n\n**SECURITIES\nAND EXCHANGE COMMISSION**\n\n**WASHINGTON,\nD.C. 20549**\n\n \n\n**FORM\n10-K/A**\n\n**(Amendment\nNo. 1)**\n\n \n\n**(Mark\nOne)**\n\n \n\n☒\n**ANNUAL\nREPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\n**FOR\nTHE FISCAL YEAR ENDED DECEMBER 31, 2025**\n\n \n\n**OR**\n\n \n\n☐\n**TRANSITION\nREPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\n**FOR\nTHE TRANSITION PERIOD FROM _________TO__________**\n\n \n\n**COMMISSION\nFILE NUMBER 001-40943**\n\n \n\n**BIOFRONTERA\nINC.**\n\n**(Exact\nname of registrant as specified in its charter)**\n\n \n\n**Delaware**\n \n**47-3765675**\n\n**(State\nor other jurisdiction of**\n\n**incorporation\nor organization)**\n\n \n\n**(I.R.S.\nEmployer**\n\n**Identification\nNo.)**\n\n \n \n \n\n**660\nMain Street, 1st Floor**\n \n \n\n**Woburn,\nMassachusetts**\n \n**01801**\n\n**(Address\nof principal executive offices)**\n \n**(Zip\ncode)**\n\n \n\n**(781)\n245-1325**\n\n**(Registrant’s\ntelephone number, including area code)**\n\n \n\n**Securities\nregistered pursuant to Section 12(b) of the Act:**\n\n \n\n**Title\nof Each Class:**\n \n**Trading\nsymbol(s)**\n \n**Name\nof Each Exchange on Which Registered:**\n\nCommon\nStock, par value $0.001 per share\n \nBFRI\n \nThe\nNasdaq Stock Market LLC\n\nWarrants\nfor common stock\n \nBFRIW\n \nThe\nNasdaq Stock Market LLC\n\n \n\n**Securities\nregistered pursuant to Section 12(g) of the Act:**\n\n**None**\n\n \n\nIndicate\nby check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒\n\n \n\nIndicate\nby check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒\n\n \n\nIndicate\nby check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange\nAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)\nhas been subject to such filing requirements for the past 90 days. Yes ☒ No ☐\n\n \n\nIndicate\nby check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule\n405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant\nwas required to submit such files). Yes ☒ No ☐\n\n \n\nIndicate\nby check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting\ncompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”\n“smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\n \n\nLarge\naccelerated filer\n☐\nAccelerated\nfiler\n☐\n\n \n \n \n \n\nNon-accelerated\nfiler\n☒\nSmaller\nreporting company\n☒\n\n \n \n \n \n\nEmerging\ngrowth company\n☒\n \n \n\n \n\nIf\nan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying\nwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\n \n\nIndicate\nby check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness\nof its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered\npublic accounting firm that prepared or issued its audit report. ☐\n\n \n\nIf\nsecurities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant\nincluded in the filing reflect the correction of an error to previously issued financial statements. ☐\n\n \n\nIndicate\nby check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation\nreceived by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐\n\n \n\nIndicate\nby check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐ No ☒\n\n \n\nAs\nof June 30, 2025, the last day of the registrant’s most recently completed second fiscal quarter, the aggregate market value of\nthe common stock held by non-affiliates of the registrant was $6.9 million, based on the closing price of the registrant’s common\nstock.\n\n \n\nAs\nof March 16, 2026, there were 11,648,323 shares outstanding of the registrant’s common stock, par value $0.001 per share.\n\n \n\n**DOCUMENTS\nINCORPORATED BY REFERENCE:**\n\n \n\nPortions of the Proxy Statement for the 2026 Annual Meeting of Stockholders of Biofrontera Inc. (the “Company”) are incorporated by\nreference into Part III of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”)\non March 19, 2026 (the “Original 10-K”). This Amendment No. 1 to Annual Report on Form 10-K (this “Form 10-K/A”) does not amend Part III of the Original 10-K.\n\n \n\n \n\n \n\n \n\n \n\n \n\n**EXPLANATORY\nNOTE**\n\n** **\n\nThe\nCompany is filing this Form 10-K/A to amend the Original 10-K solely to include Exhibit 3.3 in the exhibit index and to make other minor\nchanges to the exhibit index. Pursuant to Rule 12b-15 under the Securities Exchange Act of 1934, as amended, this Form 10-K/A also contains\nnew certifications by the Company’s principal executive officer and principal financial officer as required by Section 302 of the\nSarbanes-Oxley Act of 2002. Because no financial statements have been included in this Form 10-K/A and this Form 10-K/A does not contain\nor amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4 and 5 of the certifications have been omitted.\nAccordingly, this Form 10-K/A consists solely of the cover page, this explanatory note, the exhibit index, and the exhibits filed herewith\nor incorporated by reference herein.\n\n \n\nThe\nCompany has made no attempt in this Form 10-K/A to modify or update the Original 10-K other than as noted in the previous paragraph.\nExcept as noted above, this Form 10-K/A does not reflect events occurring after the filing of the Original 10-K. Accordingly, this Form\n10-K/A should be read in conjunction with the Original 10-K and the Company’s other filings with the SEC subsequent to the filing\nof the Original 10-K, including any amendments thereto.\n\n \n\n \n\n \n\n** **\n\n**PART\nIV**"}